ESMO 2017 | Grant McArthur on the 3 positive melanoma trials presented at the ESMO 2017 Congress

Name: Grant McArthur on the 3 positive melanoma trials presented at the ESMO 2017 Congress
Uploaded: 2017-09-11T06:34:05.000Z
Duration: 3 min 45 s
Description: We spoke to Grant McArthur during the ESMO 2017 Congress in Madrid, Spain to get his take on the exciting new data presented in melanoma during the meeting. As well as commenting on the data of the COMBI-AD, BRIM8 and CheckMate 238 trials, he also emphasizes how well tolerated some of these medicines have been.

Grant McArthur • 11 Sep 2017

ESMO 2017

Melanoma Dabrafenib Nivolumab Trametinib

BRIM8 CheckMate 238 COMBI-AD

We spoke to Grant McArthur during the ESMO 2017 Congress in Madrid, Spain to get his take on the exciting new data presented in melanoma during the meeting. As well as commenting on the data of the COMBI-AD, BRIM8 and CheckMate 238 trials, he also emphasizes how well tolerated some of these medicines have been.